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Abstract 
Background: Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre‑ and 
post‑chemotherapy metastatic castration‑resistant prostate cancer (mCRPC). Several retrospective analysis suggested 
clinical cross‑resistance between these agents in patients previously treated with docetaxel. However, data on the 
antitumor activity of AA as a second androgen receptor‑targeting new agent after the failure of enzalutamide in 
chemotherapy‑naive mCRPC patients is unavailable.
Methods: Patients with chemotherapy‑naïve mCRPC who were treated with AA after disease progression with enza‑
lutamide, were retrospectively reviewed at five institutions. Primary outcome measure was the rate of any prostate‑
specific antigen (PSA) decline. Secondary outcome measures were progression‑free survival (PFS) and overall survival 
(OS) with subsequent AA treatment. We also performed correlation analysis between previous PSA response, PFS 
duration to enzalutamide and subsequent PSA response, PFS duration to AA.
Results: A total of 14 patients were identified. Any PSA declines and PSA decline ≥50 % with AA treatment, were 
observed in 36 and 7 % of patients, respectively. Median PFS with initial enzalutamide was 5.0 months (95 % CI 
3.7–6.4 months), and for subsequent AA treatment was 3.4 months (95 % CI 0.8–6.0 months). Median OS from initia‑
tion of AA was 9.1 months (95 % CI 5.6–12.5 months). No significant correlations were observed between these PSA 
responses (Pearson r = −0.67, p = 0.82) and PFS duration (Kendall tau r = 0.33, p = 0.87).
Conclusions: The PSA decline with subsequent AA treatment in chemotherapy‑naive mCRPC patients after a failure 
of enzalutamide was modest, however, the PFS and OS with subsequent AA treatment were comparable to those 
of enzalutamide previously reported as a second androgen receptor‑targeting new agent after AA failure. The PSA 
response and PFS duration to previous enzalutamide treatment did not predict those of subsequent AA treatment.
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Background
Prostate cancer, as the second most common male cancer 
worldwide [1], and the third most common cause of male 
cancer deaths in developed countries, is a major health 
concern [2]. These trends are no exception in Japan, 
where the number of prostate cancer patients has been 
rapidly increasing. Recently, the Cancer Information Ser-
vice of the National Cancer Center of Japan, indicated 
that prostate cancer was projected to become the most 
common cancer, and the cause of a sixth of cancer deaths 
among men in Japan in 2015 [3].
Prostate cancer is initially an androgen-dependent 
disease and responds well to androgen-deprivation 
treatment (ADT) [4]. However, almost all patients, unfor-
tunately, experience disease progression during ADT 
within several years, despite attaining a castrate levels of 
testosterone, at which point they are described as having 
metastatic castration-resistant prostate cancer (mCRPC) 
[5]. After developing mCRPC, this disease state is consid-
ered incurable and life-threatening [6].
Until recently, docetaxel was the only approved agent 
that improved overall survival in mCRPC patients. How-
ever, several relatively new agents have induced promis-
ing improvements in overall survival in patients with 
mCRPC, and have, consequently, been introduced into 
daily clinical practice. Of these new agents, abirater-
one acetate (AA) [7, 8] and enzalutamide [9, 10] are oral 
agents whose mechanism of action is through an andro-
gen receptor (AR) signaling pathway. AA and enzaluta-
mide have already been approved for mCRPC patients, 
regardless of prior docetaxel treatment, based on positive 
results from a large randomized phase 3 trial. The success 
of new agents that target the AR means that the AR sign-
aling pathway remains an important driver of prostate 
cancer in the castration-resistant state [11]. Both AA and 
enzalutamide are increasingly being used in chemother-
apy-naïve patients with mCRPC for their efficacy, as well 
as for their, favorable toxicity profiles.
In spite of the rapid introduction of AA and enzaluta-
mide into daily practice, several clinical questions con-
cerning new AR-target agents remain unanswered. A 
major clinical question is whether another subsequent 
AR-targeting agent will still retain antitumor activ-
ity after becoming AR-targeted agent resistant. Several 
small retrospective analyses reported on the efficacy of 
enzalutamide in mCRPC patients after progressing on 
AA. However, almost all of these analyses were restricted 
to patients who had already been treated with docetaxel 
[12–15], and only one small study investigated chem-
otherapy-naïve patients [16]. In addition, treatment in 
the reverse sequence, enzalutamide followed by AA, has 
been reported in only patients who had already been 
treated with docetaxel [17, 18]. Based on these results of 
sequential treatment with new AR-targeting agents, the 
efficacy of a second AR-targeting agent was modest, with 
median time to progression of approximately 3–4 months.
To the best of our knowledge, published data on 
chemotherapy-naïve mCRPC patients treated with enza-
lutamide and followed by AA have not been reported as 
yet. We assume the antitumor activity of AA treatment 
in chemotherapy-naïve mCRPC patients after progress-
ing with enzalutamide might also be modest. The objec-
tives of the current retrospective analysis, therefore, were 
to reveal the efficacy and clinical outcome of AA treat-
ment in chemotherapy-naïve mCRPC patients who had 
previously undergone treatment with enzalutamide. In 




We conducted a multicenter retrospective study which 
was performed in five institutions (National Cancer 
Center Hospital East, Yokohama City University Hos-
pital, Kitasato University Hospital, Toho University 
Sakura Medical Center and Saitama Medical Center 
Saitama Medical University). This study was carried out 
in accordance with the Declaration of Helsinki and Japa-
nese ethical guidelines for epidemiological research. We 
obtained institutional review board waivers from all par-
ticipating institutional review board chairpersons to con-
duct this study.
Chemotherapy-naïve patients with mCRPC who had 
been treated with enzalutamide until the time of dis-
ease progression, and who were subsequently treated 
with AA, were eligible for this analysis. CRPC patients 
were defined based on evidence of disease progression 
(clinical, radiographic or prostate-specific antigen (PSA) 
elevation) despite castrate serum testosterone levels and 
continuous luteinizing hormone-releasing hormone ana-
logues/antagonist treatment. Patients with non-meta-
static CRPC, or who were treated with docetaxel before 
the initiation of enzalutamide, were excluded in this 
analysis. Treatment with enzalutamide continued until 
the time of disease progression according to the Pros-
tate Cancer Working Group 2 criteria [19]. Patients who 
discontinued treatment with enzalutamide due to unac-
ceptable toxicity were excluded from this analysis. This 
retrospective study investigated the direct anti-tumor 
activity of AA treatment in chemotherapy-naïve mCRPC 
patients who were resistant to enzalutamide treatment. 
Therefore, in this analysis, all patients experienced dis-
ease progression with enzalutamide.
Between the termination of enzalutamide, and the ini-
tiation of AA treatment, patients treated with any vin-
tage hormonal manipulations, such as first-generation 
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anti-androgen receptor inhibitor (flutamide, bicalta-
mide), steroid (dexamethasone, prednisolone) and estro-
gen agent, were allowed into this study, but if treated 
with any chemotherapy or investigational drugs, patients 
were excluded.
All data of patient characteristics and treatment 
outcomes with enzalutamide and AA were collected 
retrospectively from medical records of individual insti-
tutions. Information on the following parameters were 
made available for all patients: age, Gleason score, prior 
treatment history with vintage hormonal manipulations, 
serum PSA at the time of baseline enzalutamide and AA 
initiation, number and sites of metastasis, Eastern Coop-
erative Oncology Group (ECOG) performance status 
(PS), serum PSA level during treatment, treatment dura-
tion with enzalutamide and AA, type of disease progres-
sion with enzalutamide and AA, and survival status.
Outcomes measurement and statistics
The primary outcome measure of this investigation was 
to investigate the frequency of any PSA decline from 
baseline. Any PSA decline was defined as a PSA decrease 
from baseline, regardless of degree of decrease dur-
ing subsequent AA treatment. The secondary outcome 
measures were PFS and overall survival (OS) with subse-
quent AA treatment. PFS was defined as the time from 
the initiation of AA treatment to PSA progression or 
radiographic progression according to PCWG2 criteria 
[19], or clinical progression. OS was defined as the time 
from initiation of AA to death from any cause or censor-
ing on 30 November 2015. Kaplan–Meier estimates were 
used for PFS and OS. A correlation analysis between fac-
tors were evaluated using Kendall tau or Pearson correla-
tion test, where appropriate. All tests were two-sided and 
considered significant at p < 0.05. All statistical analyses 
were performed using SPSS 22.0 statistical package for 
Windows (SPSS, IBM, Chicago, IL., USA).
Results
Patient characteristics and outcomes with previous 
enzalutamide treatment
A total of 14 patients, who experienced disease progres-
sion with enzalutamide treatment and were subsequently 
treated with AA, were eligible for this analysis. Patients 
and disease characteristics at baseline and at the time 
of initiation of enzalutamide treatment are shown in 
Table  1. Patients who had previously received a radical 
prostatectomy or radial radiation therapy made up only 
21 % of the total. The median age, at the time of the first 
enzalutamide dose, was 78  years. All patient had been 
treated with vintage hormonal manipulations, such as 
first-generation anti-androgen receptor inhibitors, ster-
oids and estrogen agents prior to the initiation of the 
enzalutamide treatment. The median number of treat-
ment line with vintage hormonal manipulations prior to 
the initiation of enzalutamide treatment was three lines, 
not including luteinizing hormone-releasing hormone 
Table 1 Patient characteristics (n = 14)
Baseline characteristics
 Gleason score, n (%)
  ≤7 1 (7)
  8 6 (43)
  9 6 (43)
  10 1 (7)
 Prior local treatment, n (%) 3 (21)
  Radical prostatectomy, n 1
  Radical radiation therapy, n 2
Patient characteristics at initiation of enzalutamide
 Median age, years (range) 78 (50–88)
 Median time from CRPC to initiation of enzalutamide, 
mo (range)
5.1 (1.3–75.4)
 ECOG PS, n (%)
  0 5 (36)
  1 6 (43)
  2 3 (21)
  ≥3 0
 Number of previous vintage hormone  
manipulations, median (range)
3 (2–7)
 Metastatic site, n (%)
  Bone 13 (100)
   EOD1 1 (7)
   EOD2 7 (50)
   EOD3 6 (43)
   EOD4 0
  Lymph node 6 (43)
  Lung 1 (7)
  Liver 1 (7)
 PSA (ng/ml), median (range) 89.9 (22.4–445.6)
 Hemoglobin (g/l), median (range) 11.4 (9.7–14.0)
 LDH (U/l), median (range) 254 (173–2028)
 ALP (U/l), median (range) 205 (99–1303)
Patient characteristics at time of initiation  
of abiraterone acetate
 Median time from enzalutamide discontinuation to 
initiation of abiraterone acetate, day (range)
1 (1–69)
 ECOG PS, n (%)
  0 3 (21)
  1 5 (36)
  2 6 (43)
  ≥3 0
 PSA (ng/ml), median (range) 38.0 (8.6–572.1)
 Hemoglobin (g/l), median (range) 11.8 (9.2–14.0)
 LDH (U/l), median (range) 202 (143–960)
 ALP (U/l), median (range) 316 (117–717)
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agonist/antagonist. The median interval between the 
development of mCRPC to the initiation of enzaluta-
mide treatment was 5.1  months. At the time of initia-
tion of enzalutamide, almost all patients (79  %) were in 
good general condition, with an ECOG PS of 0 or 1, and 
only one patient had a visceral metastasis. However, all 
patients displayed bone metastasis, and nearly half (43 %) 
had a huge bone metastasis spreading as an extent of dis-
ease (EOD) score of 3. The outcomes with previous enza-
lutamide treatment are summarized in Table  2. During 
the first round enzalutamide treatment, PSA declines of 
≥30 and ≥50 % were observed in 64 and 50 % of patients, 
respectively. Almost of all patients (93 %) achieved some 
PSA decline, regardless of degree. A waterfall plot figure 
of the maximal PSA decline with enzalutamide treatment 
is presented in Fig.  1. The types of disease progression 
were PSA progression of disease (PD) in 72  %, radio-
graphic PD in 21 % and clinical PD in 7 % of patients. The 
median PFS for patients treated with enzalutamide was 
5.0 months (95 % CI 3.7–6.4 months).
Antitumor activity with subsequent AA treatment 
in patients with enzalutamide resistance
The median interval between the last dose of enza-
lutamide and the initiation of AA was 1  day (range 
1–69 days). Only two patients (14 %) received a systemic 
treatment with another vintage hormonal manipulation 
(flutamide, dexamethasone) between the cessation of 
enzalutamide treatment and the start of AA treatment. 
Patients and disease characteristics at the time of ini-
tiation of AA treatment are shown in Table  1. Baseline 
characteristics, such as ECOG PS, and laboratory data, 
including serum PSA levels at the initiation of AA treat-
ment, were similar to those at the initiation of enzaluta-
mide treatment. All patients were started with a standard 
dose and schedule of AA, orally 1000 mg, once daily, co-
administered with 5 mg prednisone bid. A PSA decline, 
regardless of the degree of decline, was observed in 36 % 
of patients. However, PSA declines ≥30 and ≥50 % were 
observed in only 7 and 7  % of patients, respectively. A 
waterfall plot figure of maximal PSA decline with sub-
sequent AA treatment is also presented in Fig. 1. At the 
time of the censoring date, all patients had discontinued 
AA treatment due to disease progression. The type of 
disease progression was PSA PD in 57  %, radiographic 
PD in 36 % and clinical PD in 7 % of patients. No patient 
discontinued AA treatment due to unacceptable toxic-
ity. The median PFS for patients treated with AA was 
3.4  months (95  % CI 0.8–6.0  months), as shown in the 
Kaplan–Meier Fig.  2a. Until the censoring date, 8 of 14 
patients (57  %) died, and all causes of death were due 
to mCRPC. The median OS from initiation of AA was 
9.1 months (95 % CI 5.6–12.5 months), as shown in the 
Kaplan–Meier Fig. 2b.
We performed a correlation analysis between the PSA 
responses, PFS duration to prior enzalutamide and these 
to subsequent AA treatments. No significant correlations 
were observed between these PSA responses (Pearson 
r = −0.67, p = 0.82, figure not shown) and PFS duration 
(Kendall tau r = 0.33, p = 0.87, Figure not shown).
Discussion
In this retrospective analysis, we revealed the efficacy of 
AA treatment after enzalutamide failure in chemother-
apy-naïve mCRPC patients. To the best of our knowl-
edge, this is the first investigation to examine the efficacy 
of AA as a second AR-targeting agent after enzalutamide, 
but before the initiation of docetaxel treatment. Pres-
ently, this treatment sequence, enzalutamide followed by 
Table 2 Treatment outcome of  prior enzalutamide 






Any PSA decline 13 (93) 5 (36)
PSA decline ≥30 % 9 (64) 1 (7)
PSA decline ≥50 % 7 (50) 1 (7)
Median PFS, mo  
(95 % CI)
5.0 (3.7–6.4) 3.4 (0.8–6.0)
Type of progression
 PSA PD 10 (72) 8 (57)
 Radiographic PD 3 (21) 5 (36)


























Fig. 1 Waterfall plot showing maximum PSA reduction of prior 
enzalutamide and subsequent abiraterone acetate treatment in each 
patient
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AA, may be more popular than in reverse in Japan since 
the timing of approval for the use of enzalutamide and 
AA in Japan was in reverse order to that of the US and 
EU. In other words, in Japan, enzalutamide was approved 
prior to the approval of AA for mCRPC patients.
We found the treatment with AA after enzalutamide 
failure in chemotherapy-naïve patients with mCRPC 
showed limited activity. Any PSA decline, or a PSA decline 
≥30 or ≥50 % were observed in 36, 7 and 7 % of patients, 
respectively. In addition, the median PFS was 3.4 months 
(95 % CI 0.8–6.0 months). The anti-tumor activity of AA 
was inferior to that reported in clinical trials of patients 
that were chemotherapy- and enzalutamide-naïve, such as, 
COU-AA-302 [8] and JPN-201 [20]. There are several con-
ceivable reasons for this reduced efficacy of AA. Firstly, the 
disease burden and patient characteristics of our cohort 
may have been worse than those of the above registered 
clinical trials. A recent retrospective analysis from the UK 
revealed that metastatic spread is an independent predic-
tive factor to a PSA response to AA treatment [21]. In fact, 
the number of bone metastases with an EOD score at the 
time of initiation of AA treatment in the present study 
seems to indicate a greater disease burden compared with 
those of published data of registration trials.
Another plausible reason is the potential of cross-
resistance between enzalutamide and AA, in other 
words, the existence of an overlapping resistance mecha-
nism. A target common to both enzalutamide and AA is 
the AR-signaling pathway, however these differ in their 
mechanisms of activity, with enzalutamide inhibiting AR 
directly and AA inhibiting extra-gonadal and intra-tumor 
androgen synthesis. The Specific mechanism of resist-
ance to enzalutamide and AA has not yet been clearly 
identified. However, a recently published paper reported 
that the androgen receptor splice variant 7 (AR-V7) may 
have the potential to be a reliable predictive biomarker 
for AA and enzalutamide [22], in addition, a prior treat-
ment history with enzalutamide or AA was associated 
with AR-V7 positivity. These data suggest the resistance 
mechanisms for AA and enzalutamide may be over-
lap. However, this seems implausible given that 36 % of 
patients in our study achieved a PSA decline with AA 
after enzalutamide failure. In addition, one patient was 
not observed to show any PSA decline with prior enza-
lutamide treatment, but achieved a PSA decline with 
subsequent AA treatment. Our results, therefore, suggest 
that there may be different and non-overlapping mecha-
nisms of resistance for AA and enzalutamide.
The median PFS for prior enzalutamide treatment in 
chemotherapy- and AA-naïve patients of the present 
study was 5.0  months, which is shorter than those from 
previous studies. A subgroup analysis of Japanese patients 
from the PREVAIL phase 3 trial reported a median PFS 
for Japanese patients of 3.7  months [23], which is com-
parable to the median PFS of the present study. Based 
on these data, including ours, enzalutamide activity in 
Japanese patients seems to be inferior to its activity in 
non-Japanese patients. A conceivable reason for differ-
ences may depend on differences in treatment histories 
with alternate hormonal therapies before the initiation 
of enzalutamide. In Japanese daily practice, almost all 
patients receive maximum androgen blockade as an ini-
tial ADT. In the case of the failure of a maximum andro-
gen blockade, Japanese patients are generally treated with 
subsequent second- and third-line hormonal treatments 
using vintage hormonal manipulations. We postulate that 
such an intense treatment history using vintage hormonal 
manipulations prior to the initiation of enzalutamide/AA 
Fig. 2 Kaplan–Meier curve of a progression‑free survival with subse‑
quent abiraterone acetate treatment b overall survival from initiation 
of abiraterone acetate treatment
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treatment in Japanese patients affected the reduced anti-
tumor activity seen with enzalutamide AA treatment.
In contrast, the median PFS and OS with subse-
quent AA treatment in the present study was 3.4 and 
9.1  months, which is comparable to the PFS and OS of 
enzalutamide previously reported as a second AR-tar-
geting agent after AA failure. A recent published retro-
spective analysis based on US claims database indicates 
that only 30–40  % of mCRPC patients can receive doc-
etaxel treatment in the real world [24]. Collectively, our 
results and real world data suggest that AA followed by 
enzalutamide, or the reverse sequence, has the potential 
to be an alternative treatment option for patients unfit for 
docetaxel based chemotherapy. However, in order to be a 
reliable treatment option, larger prospective studies need 
to be conducted for validation.
The present investigation also revealed another impor-
tant finding that the outcomes, such as PSA changed 
and PFS duration with previous enzalutamide treatment 
could not predict subsequent outcomes with AA treat-
ment. From the correlation analysis of present study, no 
significant correlations were observed in not only the 
PSA responses but also PFS durations. These results from 
our investigation suggest that the PSA response and PFS 
duration to a prior enzalutamide treatment might not be 
useful to selecting patients for subsequent treatment.
Several potential limitations exist in the present study. 
Firstly the cohort used was small with only 14 patients, 
and therefore, our analysis may be potentially underpow-
ered. Secondly, the present investigation include only 
patients who had short PFS with enzalutamide treat-
ment, thus, our results might not be reflective of the gen-
eral mCRPC patients. Thirdly, this is a retrospectively 
designed study. Finally, the timing of the initiation of AA 
treatment, and definition of disease progression were not 
uniform, but determined on individual physicians. Thus, 
scanning intervals and scanning devices during enzaluta-
mide and AA treatment varied among patients. However, 
these procedures were similar to those of real-world clini-
cal practice. Therefore, we assume that the results from 
present study will become useful references in daily clini-
cal practice, especially for patients who do not have a suit-
able general condition for docetaxel based chemotherapy 
initiation.
Conclusions
Our investigation revealed that the PSA response to 
subsequent AA treatment in chemotherapy-naïve, and 
enzalutamide refractory mCRPC patients was modest. 
However, the PFS and OS was comparable to those of 
enzalutamide previously reported as a second AR-tar-
geting agent after AA failure. The PSA response and PFS 
duration to previous enzalutamide treatment couldn`t 
predict the efficacy of subsequent AA treatment. These 
findings require validation in a larger prospective trial.
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